Evgen Pharma PLC Grant of options (1541B)
October 06 2020 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 1541B
Evgen Pharma PLC
06 October 2020
Evgen Pharma plc
("Evgen" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that, on 5 October 2020, certain employees
and directors of the Company, including the following Persons
Discharging Managerial Responsibility ("PDMR"), were granted nil
cost options (the "Options") over a total of 4,387,547 ordinary
shares in the Company exercisable, subject to the Options vesting,
for a period of up to 10 years from the date of grant and governed
by the rules of the Evgen Pharma plc Long Term Incentive Plan
("LTIP").
PDMR Position Options granted
Dr Huw Jones Chief Executive Officer 2,978,004
------------------------- ----------------
Richard Moulson Chief Financial Officer 337,817
------------------------- ----------------
The Options will vest on the third anniversary of grant, and
other than 1,489,002 Options awarded to Dr Jones on joining the
Company and vesting if performance is satisfactory, are subject to
performance based on a combination of total shareholder return
("TSR") measured against an index of comparator companies (70%),
and performance against strategic corporate objectives over three
years (30%). The minimum TSR from the grant date to the vesting
date for any of the Options to vest is median performance against
the index. Re-testing of this performance condition after the
vesting date is not permitted.
Following this award there are 7,478,376 options in issue,
representing 5.48% of the Company's issued share capital.
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Barry Clare, Chairman
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+ 44 (0)7980 541 893 / +44
Paul McManus / Anna Dunphy (0)7876 741 001
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Huw Jones
----------------------------------------------------------- ---------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Chief Executive
----------------------------------------------------------- ---------------------------------------------------
b) Initial notification /Amendment Initial Notification
----------------------------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Evgen Pharma Plc
----------------------------------------------------------- ---------------------------------------------------
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
----------------------------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of 0.25 pence each
instrument GB00BSWYN304
Identification code
----------------------------------------------------------- ---------------------------------------------------
b) Nature of the transaction Grant of options
----------------------------------------------------------- ---------------------------------------------------
c) Currency GBP
----------------------------------------------------------- ---------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ------------------------- ------------------------
nil 2,978,004
------------------------------------------------------------------------------------------ ------------------------
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
-------------------------------------------------------------------------------------- ------------------------
f) Date of the transaction 2 October 2020
----------------------------------------------------------- ---------------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- ---------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Richard Moulson
----------------------------------------------------------- ---------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
----------------------------------------------------------- ---------------------------------------------------
b) Initial notification /Amendment Initial Notification
----------------------------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Evgen Pharma plc
----------------------------------------------------------- ---------------------------------------------------
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
----------------------------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of 0.25 pence each
instrument
GB00BSWYN304
Identification code
----------------------------------------------------------- ---------------------------------------------------
b) Nature of the transaction Grant of options
----------------------------------------------------------- ---------------------------------------------------
c) Currency GBP
----------------------------------------------------------- ---------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ------------------------- ------------------------
nil 337,817
------------------------------------------------------------------------------------------ ------------------------
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
-------------------------------------------------------------------------------------- ------------------------
f) Date of the transaction 2 October 2020
----------------------------------------------------------- ---------------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- ---------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHKKPBBABDDAKK
(END) Dow Jones Newswires
October 06, 2020 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024